Lessons learned from the Pediatric Cardiomyopathy Registry (PCMR) Study Group

James D. Wilkinson, Joslyn A. Westphal, Neha Bansal, Jason D. Czachor, Hiedy Razoky, Steven E Lipshultz

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Cardiomyopathy is a rare disorder of the heart muscle, affecting 1.13 cases per 100,000 children, from birth to 18 years of age. Cardiomyopathy is the leading cause of heart transplantation in children over the age of 1. The Pediatric Cardiomyopathy Registry funded in 1994 by the National Heart, Lung, and Blood Institute was established to examine the epidemiology of the disease in children below 18 years of age. More than 3500 children across the United States and Canada have been enrolled in the Pediatric Cardiomyopathy Registry, which has followed-up these patients until death, heart transplantation, or loss to follow-up. The Pediatric Cardiomyopathy Registry has provided the most in-depth illustration of this disease regarding its aetiology, clinical course, associated risk factors, and patient outcomes. Data from the registry have helped in guiding the clinical management of cardiomyopathy in children under 18 years of age; however, questions still remain regarding the most clinically effective diagnostic and treatment approaches for these patients. Future directions of the registry include the use of next-generation whole-exome sequencing and cardiac biomarkers to identify aetiology-specific treatments and improve diagnostic strategies. This article provides a brief synopsis of the work carried out by the Pediatric Cardiomyopathy Registry since its inception, including the current knowledge on the aetiologies, outcomes, and treatments of cardiomyopathy in children.

Original languageEnglish (US)
Pages (from-to)140-153
Number of pages14
JournalCardiology in the Young
Volume25
Issue numberS2
DOIs
StatePublished - Sep 17 2015

Fingerprint

Cardiomyopathies
Registries
Pediatrics
Heart Transplantation
Exome
National Heart, Lung, and Blood Institute (U.S.)
Canada
Myocardium
Epidemiology
Biomarkers
Parturition
Therapeutics

Keywords

  • Cardiomyopathy
  • heart failure
  • paediatrics
  • patient registry
  • Pediatric Cardiomyopathy Registry

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

Wilkinson, J. D., Westphal, J. A., Bansal, N., Czachor, J. D., Razoky, H., & Lipshultz, S. E. (2015). Lessons learned from the Pediatric Cardiomyopathy Registry (PCMR) Study Group. Cardiology in the Young, 25(S2), 140-153. https://doi.org/10.1017/S1047951115000943

Lessons learned from the Pediatric Cardiomyopathy Registry (PCMR) Study Group. / Wilkinson, James D.; Westphal, Joslyn A.; Bansal, Neha; Czachor, Jason D.; Razoky, Hiedy; Lipshultz, Steven E.

In: Cardiology in the Young, Vol. 25, No. S2, 17.09.2015, p. 140-153.

Research output: Contribution to journalArticle

Wilkinson, JD, Westphal, JA, Bansal, N, Czachor, JD, Razoky, H & Lipshultz, SE 2015, 'Lessons learned from the Pediatric Cardiomyopathy Registry (PCMR) Study Group', Cardiology in the Young, vol. 25, no. S2, pp. 140-153. https://doi.org/10.1017/S1047951115000943
Wilkinson JD, Westphal JA, Bansal N, Czachor JD, Razoky H, Lipshultz SE. Lessons learned from the Pediatric Cardiomyopathy Registry (PCMR) Study Group. Cardiology in the Young. 2015 Sep 17;25(S2):140-153. https://doi.org/10.1017/S1047951115000943
Wilkinson, James D. ; Westphal, Joslyn A. ; Bansal, Neha ; Czachor, Jason D. ; Razoky, Hiedy ; Lipshultz, Steven E. / Lessons learned from the Pediatric Cardiomyopathy Registry (PCMR) Study Group. In: Cardiology in the Young. 2015 ; Vol. 25, No. S2. pp. 140-153.
@article{13f4857a44ff4150920129b5bd559f5a,
title = "Lessons learned from the Pediatric Cardiomyopathy Registry (PCMR) Study Group",
abstract = "Cardiomyopathy is a rare disorder of the heart muscle, affecting 1.13 cases per 100,000 children, from birth to 18 years of age. Cardiomyopathy is the leading cause of heart transplantation in children over the age of 1. The Pediatric Cardiomyopathy Registry funded in 1994 by the National Heart, Lung, and Blood Institute was established to examine the epidemiology of the disease in children below 18 years of age. More than 3500 children across the United States and Canada have been enrolled in the Pediatric Cardiomyopathy Registry, which has followed-up these patients until death, heart transplantation, or loss to follow-up. The Pediatric Cardiomyopathy Registry has provided the most in-depth illustration of this disease regarding its aetiology, clinical course, associated risk factors, and patient outcomes. Data from the registry have helped in guiding the clinical management of cardiomyopathy in children under 18 years of age; however, questions still remain regarding the most clinically effective diagnostic and treatment approaches for these patients. Future directions of the registry include the use of next-generation whole-exome sequencing and cardiac biomarkers to identify aetiology-specific treatments and improve diagnostic strategies. This article provides a brief synopsis of the work carried out by the Pediatric Cardiomyopathy Registry since its inception, including the current knowledge on the aetiologies, outcomes, and treatments of cardiomyopathy in children.",
keywords = "Cardiomyopathy, heart failure, paediatrics, patient registry, Pediatric Cardiomyopathy Registry",
author = "Wilkinson, {James D.} and Westphal, {Joslyn A.} and Neha Bansal and Czachor, {Jason D.} and Hiedy Razoky and Lipshultz, {Steven E}",
year = "2015",
month = "9",
day = "17",
doi = "10.1017/S1047951115000943",
language = "English (US)",
volume = "25",
pages = "140--153",
journal = "Cardiology in the Young",
issn = "1047-9511",
publisher = "Cambridge University Press",
number = "S2",

}

TY - JOUR

T1 - Lessons learned from the Pediatric Cardiomyopathy Registry (PCMR) Study Group

AU - Wilkinson, James D.

AU - Westphal, Joslyn A.

AU - Bansal, Neha

AU - Czachor, Jason D.

AU - Razoky, Hiedy

AU - Lipshultz, Steven E

PY - 2015/9/17

Y1 - 2015/9/17

N2 - Cardiomyopathy is a rare disorder of the heart muscle, affecting 1.13 cases per 100,000 children, from birth to 18 years of age. Cardiomyopathy is the leading cause of heart transplantation in children over the age of 1. The Pediatric Cardiomyopathy Registry funded in 1994 by the National Heart, Lung, and Blood Institute was established to examine the epidemiology of the disease in children below 18 years of age. More than 3500 children across the United States and Canada have been enrolled in the Pediatric Cardiomyopathy Registry, which has followed-up these patients until death, heart transplantation, or loss to follow-up. The Pediatric Cardiomyopathy Registry has provided the most in-depth illustration of this disease regarding its aetiology, clinical course, associated risk factors, and patient outcomes. Data from the registry have helped in guiding the clinical management of cardiomyopathy in children under 18 years of age; however, questions still remain regarding the most clinically effective diagnostic and treatment approaches for these patients. Future directions of the registry include the use of next-generation whole-exome sequencing and cardiac biomarkers to identify aetiology-specific treatments and improve diagnostic strategies. This article provides a brief synopsis of the work carried out by the Pediatric Cardiomyopathy Registry since its inception, including the current knowledge on the aetiologies, outcomes, and treatments of cardiomyopathy in children.

AB - Cardiomyopathy is a rare disorder of the heart muscle, affecting 1.13 cases per 100,000 children, from birth to 18 years of age. Cardiomyopathy is the leading cause of heart transplantation in children over the age of 1. The Pediatric Cardiomyopathy Registry funded in 1994 by the National Heart, Lung, and Blood Institute was established to examine the epidemiology of the disease in children below 18 years of age. More than 3500 children across the United States and Canada have been enrolled in the Pediatric Cardiomyopathy Registry, which has followed-up these patients until death, heart transplantation, or loss to follow-up. The Pediatric Cardiomyopathy Registry has provided the most in-depth illustration of this disease regarding its aetiology, clinical course, associated risk factors, and patient outcomes. Data from the registry have helped in guiding the clinical management of cardiomyopathy in children under 18 years of age; however, questions still remain regarding the most clinically effective diagnostic and treatment approaches for these patients. Future directions of the registry include the use of next-generation whole-exome sequencing and cardiac biomarkers to identify aetiology-specific treatments and improve diagnostic strategies. This article provides a brief synopsis of the work carried out by the Pediatric Cardiomyopathy Registry since its inception, including the current knowledge on the aetiologies, outcomes, and treatments of cardiomyopathy in children.

KW - Cardiomyopathy

KW - heart failure

KW - paediatrics

KW - patient registry

KW - Pediatric Cardiomyopathy Registry

UR - http://www.scopus.com/inward/record.url?scp=84941881700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941881700&partnerID=8YFLogxK

U2 - 10.1017/S1047951115000943

DO - 10.1017/S1047951115000943

M3 - Article

VL - 25

SP - 140

EP - 153

JO - Cardiology in the Young

JF - Cardiology in the Young

SN - 1047-9511

IS - S2

ER -